{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:34:02Z","timestamp":1787009642916,"version":"build-2736575974"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Fibroblast-to-myofibroblast transition and extracellular matrix overproduction represent progressive events in chronic inflammatory and fibrotic diseases, in which TGF\u03b21 is one of the key mediators. Phosphodiesterase 4 (PDE4) acts as a proinflammatory enzyme through the degradation of cyclic adenosine monophosphate and it is overexpressed in skin fibroblasts. The study investigated how apremilast (a PDE4 inhibitor) interferes with the intracellular signalling pathways responsible for the TGF\u03b21-induced fibroblast-to-myofibroblast transition and profibrotic extracellular matrix protein synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cultured human skin fibroblasts were stimulated with TGF\u03b21 (10\u2009ng\/ml) alone or combined with apremilast (1 and 10\u2009\u03bcM) for 4, 16 and 24\u2009h. Other aliquots of the same cells were previously stimulated with TGF\u03b21 and then treated with apremilast (1 and 10\u2009\u03bcM) for 4, 16 and 24\u2009h, always under stimulation with TGF\u03b21. Gene and protein expression of \u03b1SMA, type I collagen (COL1) and fibronectin were evaluated, together with the activation of small mothers against decapentaplegic 2 and 3 (Smad2\/3) and extracellular signal-regulated kinase (Erk1\/2) proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Apremilast reduced the TGF\u03b21-induced increase in \u03b1SMA, COL1 and fibronectin gene expression at 4 and 16\u2009h, and protein synthesis at 24\u2009h of treatment in cultured fibroblasts, even for cells already differentiated into myofibroblasts by way of a previous stimulation with TGF\u03b21. Apremilast inhibited the TGF\u03b21-induced Smad2\/3 and Erk1\/2 phosphorylation at 15 and 30\u2009min.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Apremilast seems to inhibit in vitro the fibroblast-to-myofibroblast transition and the profibrotic activity induced by TGF\u03b21 in cultured human skin fibroblasts by downregulating Smad2\/3 and Erk1\/2 intracellular signalling pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa249","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T07:26:24Z","timestamp":1591341984000},"page":"3927-3938","source":"Crossref","is-referenced-by-count":14,"title":["Apremilast interferes with the TGF\u03b21-induced transition of human skin fibroblasts into profibrotic myofibroblasts:\n                    <i>in vitro<\/i>\n                    study"],"prefix":"10.1093","volume":"59","author":[{"given":"Maurizio","family":"Cutolo","sequence":"first","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Soldano","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Montagna","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Tardito","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Corallo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neurosciences, Scleroderma Unit, University of Siena, Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neurosciences, Scleroderma Unit, University of Siena, Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Tavilla","sequence":"additional","affiliation":[{"name":"Department of Health Science, Unit of Dermatology, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[{"name":"Department of Health Science, Unit of Dermatology, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[{"name":"Department of Health Science, Unit of Dermatology, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-4880","authenticated-orcid":false,"given":"Alberto","family":"Sulli","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pizzorni","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Patane","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital"},{"name":"Department of Internal Medicine, Ghent University"},{"name":"Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paolino","sequence":"additional","affiliation":[{"name":"Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2020121319250239900_keaa249-B1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.12688\/f1000research.8190.1","article-title":"The myofibroblast in wound healing and fibrosis: answered and unanswered questions","volume":"5","author":"Bochaton-Piallat","year":"2016","journal-title":"F1000Res"},{"key":"2020121319250239900_keaa249-B2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"Hinz","year":"2012","journal-title":"Am J Pathol"},{"key":"2020121319250239900_keaa249-B3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex","volume":"28","author":"Schafer","year":"2016","journal-title":"Cell Signal"},{"key":"2020121319250239900_keaa249-B4","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1007\/s00018-018-2899-4","article-title":"Fibroblast-to-myofibroblast transition in bronchial asthma","volume":"75","author":"Michalik","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"2020121319250239900_keaa249-B5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00011-016-1019-x","article-title":"Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective","volume":"66","author":"Gerarduzzi","year":"2017","journal-title":"Inflamm Res"},{"key":"2020121319250239900_keaa249-B6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13075-018-1577-0","article-title":"Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts","volume":"20","author":"Cutolo","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020121319250239900_keaa249-B7","doi-asserted-by":"crossref","first-page":"L959","DOI":"10.1152\/ajplung.00508.2007","article-title":"PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-\u03b21-stimulated fibroblasts","volume":"296","author":"Togo","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2020121319250239900_keaa249-B8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000493217","article-title":"Signaling mechanisms of myofibroblastic activation: outside-in and inside-out","volume":"49","author":"Zent","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"2020121319250239900_keaa249-B9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","article-title":"New insights into TGF-\u03b2\/Smad signaling in tissue fibrosis","volume":"292","author":"Hu","year":"2018","journal-title":"Chem Biol Interact"},{"key":"2020121319250239900_keaa249-B10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/kei124","article-title":"Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts","volume":"45","author":"Ihn","year":"2006","journal-title":"Rheumatology"},{"key":"2020121319250239900_keaa249-B11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jcp.25879","article-title":"TGF\u03b2 signaling and the control of myofibroblast differentiation: implications for chronic inflammatory disorders","volume":"233","author":"Carthy","year":"2018","journal-title":"J Cell Physiol"},{"key":"2020121319250239900_keaa249-B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00726-016-2353-6","article-title":"Dietary oxidized tyrosine (O-Tyr) stimulates TGF-\u03b21-induced extracellular matrix production via the JNK\/p38 signaling pathway in rat kidneys","volume":"49","author":"Li","year":"2017","journal-title":"Amino Acids"},{"key":"2020121319250239900_keaa249-B13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front Pharmacol"},{"key":"2020121319250239900_keaa249-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellsig.2017.11.005","article-title":"TGF-\u03b21\/p53 signaling in renal fibrogenesis","volume":"43","author":"Higgins","year":"2018","journal-title":"Cell Signal"},{"key":"2020121319250239900_keaa249-B15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugneir","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2020121319250239900_keaa249-B16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov Today"},{"key":"2020121319250239900_keaa249-B17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020121319250239900_keaa249-B18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12931-018-0759-2","article-title":"The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response","volume":"19","author":"Roberts","year":"2018","journal-title":"Respir Res"},{"key":"2020121319250239900_keaa249-B19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0962-8924(02)02294-8","article-title":"Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation","volume":"12","author":"Stork","year":"2002","journal-title":"Trends Cell Biol"},{"key":"2020121319250239900_keaa249-B20","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/rheumatology\/kez204","article-title":"Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis","volume":"58","author":"Mavropoulos","year":"2019","journal-title":"Rheumatology"},{"key":"2020121319250239900_keaa249-B21","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"2020121319250239900_keaa249-B22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14656566.2015.1034107","article-title":"Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis","volume":"16","author":"Abdulrahim","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2020121319250239900_keaa249-B23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/rheumatology\/kex454","article-title":"Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience","volume":"57","author":"Abignano","year":"2018","journal-title":"Rheumatology"},{"key":"2020121319250239900_keaa249-B24","doi-asserted-by":"crossref","first-page":"1759720X1982866","DOI":"10.1177\/1759720X19828669","article-title":"IL-12\/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis","volume":"11","author":"Kragstrup","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020121319250239900_keaa249-B25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2010.142489","article-title":"EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020121319250239900_keaa249-B26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3899\/jrheum.141070","article-title":"Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts","volume":"42","author":"Cutolo","year":"2015","journal-title":"J Rheumatol"},{"key":"2020121319250239900_keaa249-B27","first-page":"455","article-title":"Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings","volume":"27","author":"Corallo","year":"2013","journal-title":"J Biol Regul Homeost Agents"},{"key":"2020121319250239900_keaa249-B28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages","volume":"76","author":"Maier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020121319250239900_keaa249-B29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40268-019-00284-1","article-title":"Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces antigen-induced atopic dermatitis in mice","volume":"19","author":"Schafer","year":"2019","journal-title":"Drugs R D"},{"key":"2020121319250239900_keaa249-B30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Method"},{"key":"2020121319250239900_keaa249-B31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF\u03b2 signalling in fibrosis","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth Factors"},{"key":"2020121319250239900_keaa249-B32","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/bjd.16028","article-title":"Transforming growth factor-\u03b2 and psoriasis: a new link","volume":"177","author":"Gallucci","year":"2017","journal-title":"Br J Dermatol"},{"key":"2020121319250239900_keaa249-B33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-\u03b2 family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"2020121319250239900_keaa249-B34","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/sj.emboj.7601818","article-title":"TGF-\u03b2 activates Erk MAP kinase signalling through direct phosphorylation of ShcA","volume":"26","author":"Lee","year":"2007","journal-title":"EMBO J"},{"key":"2020121319250239900_keaa249-B35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1096\/fj.03-0037fje","article-title":"Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-\u03b2-dependent responses in human mesangial cells","volume":"17","author":"Hayashida","year":"2003","journal-title":"FASEB J"},{"key":"2020121319250239900_keaa249-B36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2020121319250239900_keaa249-B37","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/ijms16022320","article-title":"Cyclic nucleotide signalling in kidney fibrosis","volume":"16","author":"Schinner","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2020121319250239900_keaa249-B38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00395-011-0228-2","article-title":"Cyclic nucleotide phosphodiestarase1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodelling in the heart","volume":"106","author":"Miller","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"2020121319250239900_keaa249-B39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcp.22037","article-title":"Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition","volume":"223","author":"Selige","year":"2010","journal-title":"J Cell Physiol"},{"key":"2020121319250239900_keaa249-B40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2007.06.036","article-title":"Inhibition of TGF-\u03b2 induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase","volume":"572","author":"Dunkern","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"2020121319250239900_keaa249-B41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Exp Rev Clin Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3927\/34890304\/keaa249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3927\/34890304\/keaa249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T20:32:12Z","timestamp":1722976332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/12\/3927\/5877488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,7,28]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa249","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,7,28]]}}}